Finerenone Signals Pneumonia, COVID-19 Benefits
Secondary analyses from 13,026 people with type 2 diabetes and CKD in the finerenone pivotal trials showed that the agent was linked with less infective pneumonia and blunted COVID-19 severity.
Medscape Medical News
source https://www.medscape.com/viewarticle/983036?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/983036?src=rss
Comments
Post a Comment